三官能性抗体
↑ Jäger, Michael; Schoberth, Alexandra; Ruf, Peter; Hess, Juergen; Hennig, Michael; Schmalfeldt, Barbara; Wimberger, Pauline; Ströhlein, Michael et al. (2012-01-01). “三官能性抗体Catumaxomab(抗EpCAM×Anti-CD3)による治療を受けた悪性腹水患者の第2/3相試験に関する免疫モニタリング結果(Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3))” (英語). Cancer Research 72 (1): 24–32. doi:10.1158/0008-5472.CAN-11-2235. ISSN 0008-5472. https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201202234217099283.
↑ Chames, P; Baty, D (2009). “Bispecific antibodies for cancer therapy: the light at the end of the tunnel”. MAbs 1 (6): 1–9. doi:10.4161/mabs.1.6.10015. PMC 2791310.
↑ “Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study”. Cancer Immunology, Immunotherapy 56 (10): 1637–1644. (2007). doi:10.1007/s00262-007-0310-7. PMID 17410361.
↑ “Phase I trial of the trifunctional antibody anti-HER2/neu x anti-CD3 antibody ertumaxomab in metastatic breast cancer”. Clinical Cancer Research 12 (10): 3085–3091. (2006). doi:10.1158/1078-0432.CCR-05-2436. PMID 16707606.
↑ “Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion”. Bone Marrow Transplantation 43 (5): 383–397. (2008). doi:10.1038/bmt.2008.323. PMID 18850012.